Dialysis-Associated Hypertension Treated with Telmisartan – DiaTel: A Pilot, Placebo-Controlled, Cross-Over, Randomized TrialReport as inadecuate




Dialysis-Associated Hypertension Treated with Telmisartan – DiaTel: A Pilot, Placebo-Controlled, Cross-Over, Randomized Trial - Download this document for free, or read online. Document in PDF available to download.

Treatment of hypertension in hemodialysis HD patients is characterised by lack of evidence for both the blood pressure BP target goal and the recommended drug class to use. Telmisartan, an Angiotensin receptor blocker ARB that is metabolised in the liver and not excreted via HD extracorporeal circuit might be particularly suitable for HD patients. We designed and conducted a randomised, placebo-controlled, double-blind and cross-over trial for treatment of dialysis–associated hypertension with telmisartan 80 mg once daily or placebo on top of standard antihypertensive treatment excluding other Renin-Angiotensin-System RAS blockers. In 29 patients after randomization we analysed BP after a treatment period of 8 weeks, while 13 started with telmisartan and 16 with placebo; after 8 weeks 11 continued with telmisartan and 12 with placebo after cross-over, respectively. Patients exhibited a significant reduction of systolic pre-HD BP from 141.9±21.8 before to 131.3±17.3 mmHg after the first treatment period with telmisartan or placebo. However, no average significant influence of telmisartan was observed compared to placebo. The latter may be due to a large inter-individual variability of BP responses reaching from a 40 mmHg decrease under placebo to 40 mmHg increase under telmisartan. Antihypertensive co-medication was changed for clinical reasons in 7 out of 21 patients with no significant difference between telmisartan and placebo groups. Our starting hypothesis, that telmisartan on top of standard therapy lowers systolic office BP in HD patients could not be confirmed. In conclusion, this small trial indicates that testing antihypertensive drug efficacy in HD patients is challenging due to complicated standardization of concomitant medication and other confounding factors, e.g. volume status, salt load and neurohormonal activation, that influence BP control in HD patients.

Trial Registration

Clinicaltrialsregister.eu 2005-005021-60



Author: Matthias Huber , Till Treutler , Peter Martus, Antje Kurzidim, Reinhold Kreutz, Joachim Beige

Source: http://plos.srce.hr/



DOWNLOAD PDF




Related documents